Catalyst Dossier · compiled by CeliA 🧫

Amgen Inc. (AMGN)

Biological Products, (No Diagnostic Substances) · market cap $182.2B · as of 2026-07-13

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-19 (est.)

Phase 3

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Amgen Inc. (AMGN) is a large-cap biopharmaceutical company with $36.8B in 2025 revenue, a diversified pipeline spanning oncology, inflammation, and bone disease, and a market cap of ~$196B. Its lead pipeline asset is tarlatamab, a DLL3xCD3 BiTE antibody in Phase 3 for small cell lung cancer (SCLC), carrying orphan, fast-track, and breakthrough designations. The company carries significant net debt of ~$50.7B, largely reflecting the 2023 Horizon Therapeutics acquisition, but generates substantial free cash flow to service it.

The catalyst path

2026-08-19 (est.)Phase 3 · Dazodalibepimp 9/10
2026-10-22 (est.)Phase 3 · Dazodalibepimp 9/10
2026-10-31 (est.)Phase 2 · AMG 193imp 7/10
2026-11-30 (est.)Phase 2 · Docetaxelimp 7/10
2026-12-14 (est.)Phase 3 · ABP 234imp 9/10
2027-01-21 (est.)Phase 3 · Maridebart cafraglutideimp 9/10
2027-02-22 (est.)Phase 2 · AMG 732imp 7/10
2027-04-13 (est.)Phase 2 · Inebilizumabimp 7/10

Pipeline

Asset	Phase	Indication
Rozibafusp Alfa	Phase 2	Systemic Lupus Erythematosus (SLE)
Lumakras	Approved	KRAS G12C NSCLC
Tarlatamab	Phase 3	Small Cell Lung Cancer
AMG 509	Phase 1	Prostate Cancer
Etanercept Liquid	Phase 3	Rheumatoid Arthritis
romosozumab HCP administration with PFS	Phase 3	Post-Menopausal Osteoporosis
CC10004	Phase 2	Psoriasis
Denosumab (AMG 162)	Phase 3	Postmenopausal Osteoporosis
AMG 162 / Denosumab	Phase 3	Breast Cancer
Darbepoetin alfa - 2.25 mcg/kg	Phase 3	Anemia
Etoposide	Phase 3	Small-cell Lung Cancer
ABP 206	Phase 3	Melanoma
Adecatumumab	Phase 2	Liver Metastases
AMG 531 (Romiplostim)	Phase 2	MDS
Apremilast tablet 20 mg	Phase 3	Ankylosing Spondyloarthritis
IV Bisphosphonates	Phase 2	Breast Cancer
50 mg Etanercept	Phase 3	Rheumatoid Arthritis
Epoetin alfa DT	Phase 3	Chronic Kidney Disease
Romosozumab	Phase 3	Postmenopausal Women With Osteoporosis
Abiraterone	Phase 3	Metastatic Castration-resistant Prostate Cancer

Price & technical context

3-month

+22.3%

6-month

+10.6%

12-month

+42.2%

52-wk range

$271.18–$407.83

vs 50-day MA

+12.3%

vs 200-day MA

+17.1%

Realized vol

37.6%

Max drawdown

-23.4%

Daily closes through 2026-08-06. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AMGN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.